Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Background: Preclinical blood pressure (BP) data from studies of hypoglycemic effects of
liraglutide treatment (the LEAD program), revealed a significant antihypertensive potential.
The time course and the mechanism behind this effect are unknown.
Objectives: To evaluate the time course of the antihypertensive effect of liraglutide
treatment in patients with type 2 diabetes
Design: Open-label study with intervention and subsequent washout period
Patient Population: 35 hypertensive (SBP ≥130 mm Hg and DBP ≥80 mmHg) patients with type 2
diabetes.
Intervention: All patients will be treated with liraglutide 0.6 mg once daily for 7 days and
will then be titrated to 1.2 mg once daily for 14 days and then titrated to 1.8 mg once daily
for 4 weeks. This is followed by a washout period of 3 weeks without liraglutide treatment.
Endpoints: 24-hour blood pressure, natriuresis, extra cellular volume (ECV